Table 2.
Pancreatic cancer cell lines and corresponding EMSY expression level
| Cell lines | EMSY mRNA expression ratio | BRCA2 mutation status [17] | Fancd2 mono-ubiquitination [44] | Hypersensitivity to MMC [44] |
|---|---|---|---|---|
| Colo357 | 2.1 | pos | NA | |
| PL14 | 2.2 | NA | NA | |
| Hs766T | 1 | neg | pos | |
| CFPAC1 | 2 | LOH | pos | NA |
| BxPC3 | 1.5 | LOH | pos | neg |
| PL4 | 3.1 | NA | NA | |
| PaCa2 | 0.9 | NA | NA | |
| PL11 | 1.2 | neg | pos | |
| Su86.86 | 2.7 | LOH | pos | neg |
| CAPAN2 | 2.3 | pos | NA | |
| PL3 | 3 | pos | NA | |
| PL9 | 2.5 | NA | NA | |
| PL6 | 2 | pos | NA | |
| PL1 | 1.1 | NA | NA | |
| PL12 | 2.6 | NA | NA | |
| Aspe1 | 2 | NA | NA | |
| CAPAN1 | 2.6 | 6174delT/LOH | pos | pos |
| MiaPaCa | 3.4 | NA | NA | |
| AsPC1 | 3.1 | LOH | pos | NA |
| Panc-1 | 4.1 | LOH | pos | NA |
LOH, loss of heterozygosity; del, deletion; pos, positive; neg, negative; NA, not applicable